Trial Profile
Study of the Immunological Efficacy of Using Subcutaneous Interleukin-2 (IL-2) in Antiretroviral Naive HIV-1-Infected Subjects With a CD4 Cell Count Above 300/mm3. ANRS 119 Trial INTERSTART
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms INTERSTART
- 25 Feb 2007 Status changed from in progress to completed
- 04 Jan 2006 New trial record.